Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Biotech and Neurotrauma Events

Oragenics Inc. (NYSE American: OGEN) has announced its participation in two pivotal events in 2025, the BIO International Convention and the National Neurotrauma Society Symposium, where it will spotlight ONP-002, its innovative intranasal neurosteroid candidate for concussion treatment. Greg Gironda, Head of Business Development at Oragenics, will present at the BIO International Convention in Boston, while the company also attends the Neurotrauma Symposium in Philadelphia. These platforms offer Oragenics the opportunity to engage with global leaders in neuroscience and pharmaceuticals, underscoring the significance of ONP-002 in addressing mild traumatic brain injury (mTBI), commonly known as concussion.

The development of ONP-002 represents a critical advancement in the treatment of concussions, a condition that affects millions worldwide with limited treatment options currently available. By focusing on nasal delivery of pharmaceutical medications, Oragenics is at the forefront of innovative treatment solutions that could revolutionize patient care in neurology. The company's presence at these esteemed events not only highlights the potential of ONP-002 but also emphasizes the growing importance of neurosteroids in treating brain injuries and other neurological disorders.

For the pharmaceutical industry and healthcare sector, the advancement of ONP-002 could signal a shift towards more effective and less invasive treatment options for mTBI, offering hope to patients and clinicians alike. The broader implications of this development extend to sports medicine, military health, and accident recovery, where concussions are a prevalent concern. Oragenics' commitment to addressing unmet medical needs through innovative solutions like ONP-002 underscores the importance of continued investment and research in biotechnology and neurology.